Gilead Sciences Inc
NASDAQ:GILD

Watchlist Manager
Gilead Sciences Inc Logo
Gilead Sciences Inc
NASDAQ:GILD
Watchlist
Price: 114.09 USD 0.41% Market Closed
Market Cap: 141.6B USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+12%
Revenue
Forecast
+4%
Operating Income
Forecast
+12%
Net Income
Forecast
+191%

Wall Street
Price Targets

GILD Price Targets Summary
Gilead Sciences Inc

Wall Street analysts forecast GILD stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for GILD is 128.04 USD with a low forecast of 98.98 USD and a high forecast of 150.15 USD.

GILD Lowest Forecast
Wall Street Target
98.98 USD
13% Downside
GILD Average Forecast
Wall Street Target
128.04 USD
12% Upside
GILD Highest Forecast
Wall Street Target
150.15 USD
32% Upside
Lowest
Price Target
98.98 USD
13% Downside
Average
Price Target
128.04 USD
12% Upside
Highest
Price Target
150.15 USD
32% Upside
Gilead Sciences Inc Competitors:
Price Targets
002007
Hualan Biological Engineering Inc
22% Upside
LYEL
Lyell Immunopharma Inc
14% Downside
LENZ
Graphite Bio Inc
20% Upside
002252
Shanghai RAAS Blood Products Co Ltd
7% Upside
002007
Hualan Biological Engineering Inc
22% Upside
LYEL
Lyell Immunopharma Inc
14% Downside
LENZ
Graphite Bio Inc
20% Upside
002252
Shanghai RAAS Blood Products Co Ltd
7% Upside
ADCT
ADC Therapeutics SA
146% Upside
ELDN
Eledon Pharmaceuticals Inc
284% Upside
300294
China Resources Boya Bio pharmaceutical Group Co Ltd
35% Upside

Revenue
Forecast

Revenue Estimate
Gilead Sciences Inc

For the last 13 years the compound annual growth rate for Gilead Sciences Inc's revenue is 10%. The projected CAGR for the next 3 years is 4%.

10%
Past Growth
4%
Estimated Growth
Estimates Accuracy
-1%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Gilead Sciences Inc

For the last 13 years the compound annual growth rate for Gilead Sciences Inc's operating income is 8%. The projected CAGR for the next 3 years is 12%.

8%
Past Growth
12%
Estimated Growth
Estimates Accuracy
-11%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Gilead Sciences Inc

For the last 13 years the compound annual growth rate for Gilead Sciences Inc's net income is -13%. The projected CAGR for the next 3 years is 191%.

-13%
Past Growth
191%
Estimated Growth
Estimates Accuracy
-36%
Average Miss
What are analyst estimates?

See Also

Summary
GILD intrinsic value, competitors valuation, and company profile.
DCF Valuation
GILD stock valuation using Discount Cash Flow valuation method.
Relative Valuation
GILD stock valuation using valuation multiples.
Wall Street Estimates
GILD price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
GILD stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is GILD's stock price target?
Price Target
128.04 USD

According to Wall Street analysts, the average 1-year price target for GILD is 128.04 USD with a low forecast of 98.98 USD and a high forecast of 150.15 USD.

What is Gilead Sciences Inc's Revenue forecast?
Projected CAGR
4%

For the last 13 years the compound annual growth rate for Gilead Sciences Inc's revenue is 10%. The projected CAGR for the next 3 years is 4%.

What is Gilead Sciences Inc's Operating Income forecast?
Projected CAGR
12%

For the last 13 years the compound annual growth rate for Gilead Sciences Inc's operating income is 8%. The projected CAGR for the next 3 years is 12%.

What is Gilead Sciences Inc's Net Income forecast?
Projected CAGR
191%

For the last 13 years the compound annual growth rate for Gilead Sciences Inc's net income is -13%. The projected CAGR for the next 3 years is 191%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 283,400+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.